NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) ...

At 34, non-smoker Reyna Savage mistook persistent shoulder pain for a gym injury, only to be diagnosed with stage 4 non-small ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

The researchers found that non-smokers were likely to develop non-small cell lung cancer, like Ms Savage. The group of international scientists found the most dominant form of the disease is now ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso® (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes ...